Treatment for Amphetamine Abuse

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Friends Research Institute, Los Angeles, CA
Amphetamine Abuse+2 More
Eligibility
18 - 65
All Sexes
Eligible conditions
Select

Study Summary

This study is evaluating whether cocaine or methamphetamine use alters DA synthesis capacity or DA transporter availability in the striatum.

See full description

Eligible Conditions

  • Amphetamine Abuse
  • Tobacco Dependence

Treatment Effectiveness

Effectiveness Progress

1 of 3

Trial Safety

Safety Progress

1 of 3

Trial Design

0 Treatment Group

This trial involves 0 different treatment group

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 5 years
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly up to 5 years for reporting.

Closest Location

Friends Research Institute - Los Angeles, CA

Eligibility Criteria

This trial is for patients born any sex between 18 and 65 years old. There is one eligibility criterion to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
M/F, ages 21-50. Meet DSM-IV criteria for methamphetamine and nicotine dependence. Agree to conditions of the study and sign informed consent.

Patient Q&A Section

Ask a question about the study

Other questions from users

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any geographic restrictions to consider when applying for this trial?

Patients from any state can participate in this trial, so long as they are able to attend all treatment sessions.

Will my insurance cover participating in this trial?

There is not cost involved in participating in this trial, so insurance won't be necessary.

See if you qualify for this trial
Get access to this novel treatment for Amphetamine Abuse by sharing your contact details with the study coordinator.